Cantor Fitzgerald analyst Rick Bienkowski initiated coverage of Intellia Therapeutics with an Overweight rating and $67 price target. The firm calls Intellia "the leader in in vivo gene editing" with clinical proof-of-concept for its two lead programs, namely NTLA-2001 for TTR amyloidosis, or ATTR, and NTLA-2002 for hereditary angioedema, or HAE, prophylaxis.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics upgraded to Neutral from Sell at Citi
- JMP downgrades Intellia on lack of 2023 clinical updates
- Intellia Therapeutics downgraded to Market Perform from Outperform at JMP Securities
- Intellia awarded innovation passport in UK for NTLA-2002
- Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
